A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis

(2013) James Foran et al.   Clinical Lymphoma Myeloma & Leukemia

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

(2013) S. F. Dent et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2013) Kevin R. Kelly et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

(2013) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular heterogeneity and centrosome-associated genes in multiple myeloma

(2013) Fedor Kryukov et al.   LEUKEMIA & LYMPHOMA

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

(2013) Carlos Graux et al.   LEUKEMIA RESEARCH

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide

(2011) L. Santo et al.   CLINICAL CANCER RESEARCH

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma

(2008) Robert P. Evans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells

(2008) Robert Evans et al.   LEUKEMIA & LYMPHOMA